Literature DB >> 26360553

Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1.

Francesca Angileri1, Vincent Roy1, Geneviève Morrow1, Jean Yves Scoazec2, Nicolas Gadot2, Diana Orejuela1, Robert M Tanguay3.   

Abstract

Hereditary tyrosinemia type 1 (HT1) is the most severe inherited metabolic disease of the tyrosine catabolic pathway, with a progressive hepatic and renal injury and a fatal outcome if untreated. Toxic metabolites accumulating in HT1 have been shown to elicit endoplasmic reticulum (ER) stress response, and to induce chromosomal instability, cell cycle arrest and apoptosis perturbation. Although many studies have concentrated on elucidating these events, the molecular pathways responsible for development of hepatocellular carcinoma (HCC) still remain unclear. In this study the fah knockout murine model (fah(-/-)) was used to investigate the cellular signaling implicated in the pathogenesis of HT1. Fah(-/-) mice were subjected to drug therapy discontinuation (Nitisinone withdrawal), and livers were analyzed at different stages of the disease. Monitoring of mice revealed an increasing degeneration of the overall physiological conditions following drug withdrawal. Histological analysis unveiled diffuse hepatocellular damage, steatosis, oval-like cells proliferation and development of liver cell adenomas. Immunoblotting results revealed a progressive and chronic activation of stress pathways related to cell survival and proliferation, including several stress regulators such as Nrf2, eIF2α, CHOP, HO-1, and some members of the MAPK signaling cascade. Impairment of stress defensive mechanisms was also shown by microarray analysis in fah(-/-) mice following prolonged therapy interruption. These results suggest that a sustained activation of stress pathways in the chronic HT1 progression might play a central role in exacerbating liver degeneration.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ER stress; HO-1; Hepatoma; Hereditary tyrosinemia type 1 (HT1); Liver dysfunction; Metabolic diseases

Year:  2015        PMID: 26360553     DOI: 10.1016/j.bbadis.2015.09.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 2.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.

Authors:  Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole
Journal:  Pharmacol Ther       Date:  2016-10-19       Impact factor: 12.310

3.  Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.

Authors:  Faysal Elgilani; Shennen A Mao; Jaime M Glorioso; Meng Yin; Ianko D Iankov; Anisha Singh; Bruce Amiot; Piero Rinaldo; Ronald J Marler; Richard L Ehman; Markus Grompe; Joseph B Lillegard; Raymond D Hickey; Scott L Nyberg
Journal:  Am J Pathol       Date:  2016-11-14       Impact factor: 4.307

Review 4.  Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.

Authors:  Lucas B Sullivan; Dan Y Gui; Matthew G Vander Heiden
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

Review 5.  The association between chemical-induced porphyria and hepatic cancer.

Authors:  Andrew G Smith; John R Foster
Journal:  Toxicol Res (Camb)       Date:  2018-06-01       Impact factor: 3.524

6.  A versatile transposon-based technology to generate loss- and gain-of-function phenotypes in the mouse liver.

Authors:  Anna Georgina Kopasz; Dávid Zsolt Pusztai; Réka Karkas; Liza Hudoba; Khaldoon Sadiq Ahmed Abdullah; Gergely Imre; Gabriella Pankotai-Bodó; Ede Migh; Andrea Nagy; András Kriston; Péter Germán; Andrea Bakné Drubi; Anna Molnár; Ildikó Fekete; Virág Éva Dani; Imre Ocsovszki; László Géza Puskás; Péter Horváth; Farkas Sükösd; Lajos Mátés
Journal:  BMC Biol       Date:  2022-04-01       Impact factor: 7.431

7.  mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model.

Authors:  Maximiliano L Cacicedo; Christine Weinl-Tenbruck; Daniel Frank; Sebastian Wirsching; Beate K Straub; Jana Hauke; Jürgen G Okun; Nigel Horscroft; Julia B Hennermann; Fred Zepp; Frédéric Chevessier-Tünnesen; Stephan Gehring
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-15       Impact factor: 5.849

8.  Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1.

Authors:  Francesca Angileri; Geneviève Morrow; Jean-Yves Scoazec; Nicolas Gadot; Vincent Roy; Suli Huang; Tangchun Wu; Robert M Tanguay
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.